May. 16 at 1:15 AM
$SRTS - Revenue:
$8.3 million, a decrease year-over-year (exact prior-year figure not specified in sources), but it surpassed analyst estimates of
$7.234 million.
- Net Loss:
$2.6 million, or $(0.16) per share, compared to a profit of
$0.14 per share in Q1 2024, representing a significant decline.
- Gross Profit:
$4.4 million, with a gross margin of 52%, impacted by lower sales and higher costs.
- Earnings Surprise: Earnings missed expectations by 500%, though revenue beat estimates by 14.77%.
- Operational Highlights: Shipped 21 superficial radiotherapy (SRT) systems, including 15 to new customers, indicating continued market penetration.
- Cash Position: Strong at
$19.1 million, providing financial stability.
- Forward Guidance: Management provided optimistic guidance, expecting profitability in the next three quarters, which boosted after-hours stock price to
$5.35 (up 18%).
- by Grok
